What is the current drug of choice for treating Methicillin-resistant Staphylococcus aureus (MRSA)?

Vancomycin is considered the drug of choice for treating Methicillin-resistant Staphylococcus aureus (MRSA). This glycopeptide antibiotic is effective against Gram-positive bacteria, particularly staphylococci that are resistant to methicillin. Vancomycin works by interfering with bacterial cell wall synthesis, which is critical for the bacteria's growth and survival.

In the context of MRSA, the emergence of resistance to beta-lactam antibiotics (like methicillin) necessitates the use of alternative therapies, with vancomycin being a cornerstone of empirical treatment for serious infections caused by MRSA, especially those involving the bloodstream or skin and soft tissue. Its ability to effectively penetrate tissues and its longstanding track record of use makes it a go-to option for healthcare providers managing MRSA infections.

Other options, while they may be effective against certain strains of staphylococcus, are not the frontline treatment for MRSA due to either resistance patterns or limited efficacy in severe infections.